Gregory Knutson - 18 Mar 2022 Form 4 Insider Report for U.S. Stem Cell, Inc.

Role: Director
Signature: /s/ Gregory Knutson
Issuer symbol: USRM on OTC
Transactions as of: 18 Mar 2022
Net transactions value: +$1,250,000,200,000
Form type: 4
Filing time: 25 Mar 2022, 16:02:46 UTC
Previous filing: 04 Mar 2022
Next filing: 29 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	USRM	Common Stock	Award	$200,000	+25,000,000	+1493%	$0.008000	26,675,000	18 Mar 2022	Direct
holding	USRM	Common Stock						38,005,331	18 Mar 2022	Held by NorthStar Biotech Group, LLC of which Gregory Knutson is Managing Director

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	USRM	Convertible promissory Note (right to buy)	Award	$1,250,000,000,000	+12,500,000	+345%	$100000.00^*	16,125,000	24 Feb 2022	Common Stock	12,500,000	$0.008000	Direct	F1
transaction	USRM	Warrant	Award		+12,500,000	+78%		28,625,000	24 Feb 2022	Common Stock	12,500,000	$0.008000	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Previously reported; By addendum the conversion price was adjusted and the maturity date extended.
F2	Issued in consideration of the extension of the extension of the maturity date.
F3	The Warrant was revised to disclose an expiration date of 02/24/2027.